Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

被引：3

作者：

Callander, Natalie S. ^{[1
]}

Silbermann, Rebecca ^{[2
]}

Kaufman, Jonathan L. ^{[3
]}

Godby, Kelly N. ^{[4
]}

Laubach, Jacob ^{[5
]}

Schmidt, Timothy M. ^{[1
]}

Sborov, Douglas W. ^{[6
]}

Medvedova, Eva ^{[2
]}

Reeves, Brandi ^{[7
]}

Dhakal, Binod ^{[8
]}

Rodriguez, Cesar ^{[9
]}

Chhabra, Saurabh ^{[8
]}

Chari, Ajai ^{[9
]}

Bal, Susan ^{[4
]}

Anderson, Larry D. ^{[10
]}

Dholaria, Bhagirathbhai R. ^{[11
]}

Nathwani, Nitya ^{[12
]}

Hari, Parameswaran ^{[8
]}

Shah, Nina ^{[13
]}

Bumma, Naresh ^{[14
]}

Holstein, Sarah A. ^{[15
]}

Costello, Caitlin ^{[16
]}

Jakubowiak, Andrzej ^{[17
]}

Wildes, Tanya M. ^{[15
]}

Orlowski, Robert Z. ^{[18
]}

Shain, Kenneth H. ^{[19
]}

Cowan, Andrew J. ^{[20
]}

Pei, Huiling ^{[21
]}

Cortoos, Annelore ^{[22
]}

Patel, Sharmila ^{[22
]}

Lin, Thomas S. ^{[22
]}

Giri, Smith ^{[23
]}

Costa, Luciano J. ^{[4
]}

Usmani, Saad Z. ^{[24
]}

Richardson, Paul G. ^{[5
]}

Voorhees, Peter M. ^{[25
]}

机构：

[1] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[4] Univ Alabama Birmingham, Birmingham Hosp, Birmingham, AL USA

[5] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[7] Univ N Carolina, Dept Med, Chapel Hill, NC USA

[8] Mayo Clin Arizona, Dept Med, Div Hematol Oncol, Phoenix, AZ USA

[9] Icahn Sch Med Mt Sinai, New York, NY USA

[10] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Waldenstroms & Amyloidosis Program, Dallas, TX USA

[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[12] City Hope Comprehens Canc Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA

[13] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[14] Ohio State Univ, Comprehens Canc Ctr, Div Hematol, Columbus, OH USA

[15] Univ Nebraska Med Ctr, Dept Internal Med, Div Oncol & Hematol, Omaha, NE USA

[16] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA

[17] Univ Chicago, Med Ctr, Chicago, IL USA

[18] Univ Texas MD Anderson Canc Ctr Houston, Dept Lymphoma Myeloma, Houston, TX USA

[19] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[20] Univ Washington, Div Med Oncol, Seattle, WA USA

[21] Janssen Res & Dev LLC, Titusville, NJ USA

[22] Janssen Sci Affairs LLC, Horsham, PA USA

[23] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL USA

[24] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[25] Atrium Hlth Wake Forest Baptist, Levine Canc Inst, Charlotte, NC 28203 USA

来源：

BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期

关键词：

ANTIBODY DARATUMUMAB; CONSENSUS; CRITERIA;

D O I：

10.1038/s41408-024-01030-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]). Among 123 D-KRd patients, 43.1%, 37.4%, and 19.5% had 0, 1, or >= 2 HRCAs. Among 120 D-RVd patients, 55.8%, 28.3%, and 10.8% had 0, 1, or >= 2 HRCAs. Rates of complete response or better (best on study) for 0, 1, or >= 2 HRCAs were 90.6%, 89.1%, and 70.8% for D-KRd, and 90.9%, 78.8%, and 61.5% for D-RVd. At median follow-up (MASTER, 31.1 months; GRIFFIN, 49.6 months for randomized patients/59.5 months for safety run-in patients), MRD-negativity rates as assessed by next-generation sequencing (10-5) were 80.0%, 86.4%, and 83.3% for 0, 1, or >= 2 HRCAs for D-KRd, and 76.1%, 55.9%, and 61.5% for D-RVd. PFS was similar between studies and superior for 0 or 1 versus >= 2 HRCAs: 36-month PFS rates for D-KRd were 89.9%, 86.2%, and 52.4%, and 96.7%, 90.5%, and 53.5% for D-RVd. These data support the use of daratumumab-containing regimens for transplant-eligible NDMM with HCRAs; however, additional strategies are needed for ultra-high-risk disease (>= 2 HRCAs).Video Abstract 935yYg7rG1hc1uCFy66-b8

引用

页数：8

共 50 条

[1] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Yvette N. Lamb
[J]. Drugs, 2020, 80 : 1455 - 1464
[2] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Lamb, Yvette N.
[J]. DRUGS, 2020, 80 (14) : 1455 - 1464
[3] Correction to: Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Yvette N. Lamb
[J]. Drugs, 2021, 81 : 183 - 183
[4] Quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma (TENDMM): A systematic review and meta-analysis
Channar, Aneeta
Naqvi, Syed Arsalan Ahmed
Khan, Muhammad Ali
Bibi, Arifa
Saxena, Akshat
Tripathi, Nikita
Iftikhar, Ahmad
Raina, Ammad
Khakwani, Kaneez Zahra Rubab
Bin Riaz, Irbaz
Husnain, Muhammad
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma
Moreau, Philippe
Giralt, Sergio A.
[J]. LEUKEMIA RESEARCH, 2012, 36 : S13 - S18
[6] Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
Callander, Natalie
Silbermann, Rebecca
Kaufman, Jonathan L.
Godby, Kelly N.
Laubach, Jacob P.
Schmidt, Timothy Martin
Sborov, Douglas W.
Medvedova, Eva
Reeves, Brandi
Dhakal, Binod
Rodriguez, Cesar
Chhabra, Saurabh
Chari, Ajai
Bal, Susan
Anderson, Larry D., Jr.
Dholaria, Bhagirathbhai
Nathwani, Nitya
Hari, Parameswaran
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Ken H.
Cowan, Andrew J.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Giri, Smith
Costa, Luciano J.
Richardson, Paul G.
Usmani, Saad
Voorhees, Peter M.
[J]. BLOOD, 2022, 140 : 10144 - 10147
[7] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
[J]. BLOOD, 2020, 136 (08) : 936 - 945
[8] Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Shaji Kumar
[J]. Current Hematologic Malignancy Reports, 2011, 6 : 104 - 112
[9] Treatment of transplant-eligible patients with newly diagnosed multiple myeloma
Nakaseko, Chiaki
[J]. ANNALS OF ONCOLOGY, 2017, 28
[10] Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Kumar, Shaji
[J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) : 104 - 112

← 1 2 3 4 5 →